226 related articles for article (PubMed ID: 29168012)
21. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
22. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.
Mac S; Sumner A; Duchesne-Belanger S; Stirling R; Tunis M; Sander B
Pediatrics; 2019 May; 143(5):. PubMed ID: 31040196
[TBL] [Abstract][Full Text] [Related]
25. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.
Mahadevia PJ; Masaquel AS; Polak MJ; Weiner LB
J Med Econ; 2012; 15(5):987-96. PubMed ID: 22574798
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.
Salinas-Escudero G; Martínez-Valverde S; Reyes-López A; Garduño-Espinosa J; Muñoz-Hernández O; Granados-García V; Rely K
Salud Publica Mex; 2012; 54(1):47-59. PubMed ID: 22286828
[TBL] [Abstract][Full Text] [Related]
27. Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.
Rodgers-Gray BS; Fullarton JR; Carbonell-Estrany X; Keary IP; Tarride JÉ; Paes BA
J Med Econ; 2023; 26(1):630-643. PubMed ID: 37067826
[TBL] [Abstract][Full Text] [Related]
28. Health economics and RSV.
Carbonell-Estrany X; Lázaro y de Mercado P
Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():12-3. PubMed ID: 19651392
[TBL] [Abstract][Full Text] [Related]
29. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
Marchetti A; Lau H; Magar R; Wang L; Devercelli G
Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
[TBL] [Abstract][Full Text] [Related]
30. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
[TBL] [Abstract][Full Text] [Related]
31. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.
Papenburg J; Saleem M; Teselink J; Li A; Caouette G; Massé É; Lanctôt KL
Pediatr Infect Dis J; 2020 Aug; 39(8):694-699. PubMed ID: 32379195
[TBL] [Abstract][Full Text] [Related]
32. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
[TBL] [Abstract][Full Text] [Related]
34. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
35. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
Ordóñez JE; Huertas VM
BMC Infect Dis; 2024 Apr; 24(1):418. PubMed ID: 38641577
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
[TBL] [Abstract][Full Text] [Related]
37. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost.
Atkins JT; Karimi P; Morris BH; McDavid G; Shim S
Pediatr Infect Dis J; 2000 Feb; 19(2):138-43. PubMed ID: 10694001
[TBL] [Abstract][Full Text] [Related]
38. The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.
Banerji A; Panzov V; Young M; Lee BE; Mamdani M; Giles BL; Dennis M; Morel J; Bisson D; Paes BA; Hui C; Mahony J
Can Respir J; 2014; 21(3):185-9. PubMed ID: 24367792
[TBL] [Abstract][Full Text] [Related]
39. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis.
Ginsberg GM; Somekh E; Schlesinger Y
Isr J Health Policy Res; 2018 Dec; 7(1):63. PubMed ID: 30554570
[TBL] [Abstract][Full Text] [Related]
40. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]